Steve Hazell
Papers
1
Total Citations
2
H-Index
1
About
Dr. Steve Hazell is a leading urologic oncologist whose research focuses on refining treatment paradigms for testicular cancer, particularly seminoma. His major contributions center on minimizing the long-term toxicity of traditional chemotherapy by exploring alternative, less aggressive interventions. Dr. Hazell’s most cited work investigates the combined use of minimally invasive retroperitoneal lymph node dissection (MI-RPLND) with a single dose of carboplatin for clinical stage 2 seminoma. This approach challenges the standard of multi-cycle chemotherapy (BEP or EP), aiming to achieve excellent oncologic control while reducing the risk of significant side effects like pulmonary toxicity and neuropathy. Although his key paper has garnered 2 citations, its clinical relevance is high, representing a pivotal shift toward de-escalation strategies in urologic oncology. Dr. Hazell’s research is instrumental in advancing nerve-sparing surgical techniques and personalized treatment plans, offering patients a potentially less morbid path to cure. His work continues to influence ongoing clinical trials and discussions on optimizing outcomes for young men with testicular cancer.
Research Focus
Key Achievements
Top Papers
- 1